<DOC>
	<DOCNO>NCT01947348</DOCNO>
	<brief_summary>To purpose study determine treatment SVF ( Stromal Vascular Fraction ) effect pain inflammation associate Osteoarthritis .</brief_summary>
	<brief_title>Safety Clinical Effectiveness A3 SVF Osteoarthritis</brief_title>
	<detailed_description>This prospective non-randomized , clinical study 30 patient determine safety treatment potential A3 ( Adult Autologous Adipose ) SVF pain inflammation associate Osteoarthritis . Patients treat Osteoarthritis due degeneration chronic injury . They give autologous SVF extract derive A3 method mixed activate platelet PRP ( platelet rich plasma ) preparation direct injection effect joint . Outcomes tracked WOMAC ( Western Ontario McMaster Universities Arthritis Index ) , AUSCAN ( Australian Hand Osteoarthritis Index ) score , general blood panel order evaluate systemic effect .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Patients indication Osteoarthritis . Can degeneration chronic injury . Patients range 1590 year age . Female patient pregnant lactate . Patients history current corticosteroid therapy eligible use suspend 1 month prior cell therapy . Patients must able comply treatment plan , laboratory test periodic interview . Patients adequate renal function , creatinine ≤ 1.5 mg/dl . Patients adequate blood coagulation activity , PT ( INR ) &lt; 1.5 , APTT &lt; 1.5×control . Diagnosis cancer within 5 year prior screen , except cutaneous basal cell squamous cell cancer resolve excision . Signs symptom clinically significant cardiac disease . Diagnosis transient ischemic attack 6 month prior screen , Known allergy anesthetic component study . Patients infect hepatitis B , C HIV . Patients Body Mass Index ( BMI ) &gt; 39kg/m2 . Any cardiovascular illness opinion investigator would render patient unsuitable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>